The Patent Finder

Enanta Pharmaceuticals, Inc.

144 patents currently held · Updated Nov 18, 2026
4 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

Recorded under 9 name spellings.

13
Ending by 2030
Feb 2027
Next term end

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 2 fees due Dec 18, 2026
  • 3 fees due Jan 21 to 30, 2027 · next Jan 21
  • 2 fees due Feb 8 to 28, 2027 · next Feb 8
  • 3 fees due Mar 3 to 19, 2027 · next Mar 3
  • 7 fees due Apr 1 to 30, 2027 · next Apr 1
  • 2 fees due May 12 to 24, 2027 · next May 12
  • 5 fees due Jun 5 to 30, 2027 · next Jun 5
  • 3 fees due Jul 2 to 26, 2027 · next Jul 2
  • 4 fees due Aug 6 to 27, 2027 · next Aug 6
  • 4 fees due Sep 5 to 24, 2027 · next Sep 5
  • 5 fees due Oct 2 to 30, 2027 · next Oct 2
  • 1 fee due Nov 7, 2027
    The maintenance fee for Spiropyrrolidine derived antiviral agents (US 11,976,084) comes due Nov 7, 2027. Unpaid by May 8, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

  • 2 of the patents on this record were granted since Aug 20, 2026
  • 6 terms have ended since Aug 20, 2026

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
PatentTitleStatus Expires Confidence
US 7,538,225Processes for the preparation of o-(6-pyrazol-1-yl-pyridin-3-ylmethyl)-hydroxylamine
In force
 · From the USPTO record
In forceFrom the USPTO record
US 7,589,0676, 11-bridged tricyclic macrolides
In force
 · From the USPTO record
In forceFrom the USPTO record
US 7,563,877Processes for the preparation of 0-(2-aminobenzo[d]oxazol-5-yl)methyl hydroxylamine for the synthesis of 6,11-bicyclic erythromycin derivative EDP-182
In force
 · From the USPTO record
In forceFrom the USPTO record
US 7,622,452C-9 alkenylidine bridged macrolides
In force
 · From the USPTO record
In forceFrom the USPTO record
US 7,906,513Hydrazide-containing hepatitis C serine protease inhibitors
In force
 · From the USPTO record
In forceFrom the USPTO record
US 8,951,998Quinoxaline-containing compounds as hepatitis C virus inhibitors
In force
 · From the USPTO record
In forceFrom the USPTO record
US 7,842,813Processes for the preparation of O-[5-(4-amino-thiazol-2-yl)-pyridin-2-ylmethyl]-hydroxylamine
In force
 · From the USPTO record
In forceFrom the USPTO record
US 8,193,346Process for Making Macrocyclic Oximyl Hepatitis C Protease Inhibitors
In force
 · High confidence
In forceHigh confidence
US 9,156,886Cyclosporin analogues for preventing or treating hepatitis C infection
In force
 · From the USPTO record
In forceFrom the USPTO record
US 8,101,643Novel Benzimidazole Derivatives
In force
 · High confidence
In forceHigh confidence
10 of 144 patents shown.
Pro members see all 144.
Pro members: see all 144 patents
Also on record, not counted in the 144: 4 patents in force now held by others · 131 lapsed for an unpaid fee · 25 ended at full term · 1 surrendered on reissue. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

15 pending · 6 abandoned · 21 no status recorded

List them

The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited